Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Lowers 2014 Guidance, Cites Delay of Contracts

Premium

NEW YORK (Genomeweb News) – Proteome Sciences this week lowered its full year 2014 guidance, citing delays in the timing of several contracts.

The company said that as a result it expects 2014 revenues to be "somewhat lower" than the £2.14 million ($3.35 million) in revenues it posted in 2013.

The company said that it expected the delayed revenues to be captured in 2015, based on strong growth in its biomarker services and TMT reagent businesses.

Proteome Sciences added that it has begun discussions with several parties regarding outlicensing its biomarkers for detection of mild cognitive impairment and Alzheimer's disease.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.